Thawing of the Bio IPO Market and the Rise of New Players

Recently, the global biotech IPO market, which had been in a slump, has begun to thaw, with Seaport Therapeutics (SPTX) and Hemab Therapeutics (COAG) launching offerings of approximately $180 million each. This signals that the solid foundation built by increased global venture capital (VC) investment and active mergers and acquisitions (M&A) by major pharmaceutical companies is now extending to the IPO market. In particular, this offering is a significant turning point, reversing the somewhat subdued sentiment in the bio IPO market that followed the brief boom in February. As investor sentiment towards risk assets improves, innovative platform technologies that have reached clinical stages are being selected by the market.

'Glyph' Liver Metabolism Bypass Platform and Novel Depression Pipeline

Seaport Therapeutics (SPTX), co-founded by Daphne Zohar of Karuna Therapeutics, is developing antidepressants using its proprietary Glyph platform technology. This platform is designed to allow oral drugs to be absorbed through the lymphatic system before passing through the liver and undergoing metabolism, increasing bioavailability and significantly reducing side effects such as hepatotoxicity. Seaport Therapeutics (SPTX) plans to invest $121 million from the IPO proceeds to complete a Phase 2b trial of SPT-300 (GlyphAllo), its lead pipeline targeting neurosteroids for the treatment of major depressive disorder (MDD), and to initiate a Phase 3 trial by next year. In addition, it plans to allocate an additional $97 million to complete a Phase 2 trial of SPT-320 (GlyphAgo), an improved version of a drug approved in Europe as Valdoxan (agomelatine) but which failed to pass the FDA review.

First-in-Class Prophylactic Hemorrhage Treatment 'Sutacimig' and Pioneering Rare Blood Disorder

Hemab Therapeutics (COAG), a Denmark- and U.S.-based rare blood disorder specialist, plans to invest $120 million to $130 million in the development of its lead bispecific antibody, sutacimig (HMB-001). Sutacimig has an innovative mechanism that simultaneously targets endogenous Factor VIIa and activated platelet TLT-1 protein, inducing coagulation factors to the site of vascular damage. It has already demonstrated excellent hemorrhage reduction in a Phase 2 trial in patients with Glanzmann thrombasthenia and has received both Breakthrough Therapy and Orphan Drug designations from the FDA. The funds secured this time will be used to focus on initiating a Phase 3 trial for Glanzmann thrombasthenia and conducting a Phase 2 trial for Factor VII deficiency, and is expected to be a game-changer for patients who have relied on existing standard treatments such as NovoSeven or platelet transfusions.

Pipeline Diversification and Sustainable Growth Strategy Based on Financial Strength

Both companies have built a solid portfolio by not relying solely on their lead pipelines. Seaport Therapeutics (SPTX) is cultivating SPT-348, a depression treatment candidate based on an LSD analog that eliminates hallucinogenic side effects, as a long-term growth driver. Hemab Therapeutics (COAG) is also allocating $60 million to $70 million to advance HMB-002, a monovalent antibody candidate for the treatment of von Willebrand disease, into a Phase 1/2 trial. As of the end of 2025, Seaport had a solid cash balance of $233.7 million, and Hemab had $185.5 million, and the success of this IPO has further strengthened their financial stability. This strong financial strength will be a strong buffer against unexpected clinical delays and will help to further develop their proprietary platform technologies.

Investment History and Wall Street's View of the Future of Biotech

Seaport Therapeutics (SPTX) was spun out of PureTech Health (PRTC) and secured large-scale investments early on, raising $100 million in Series A and $225 million in Series B. Hemab Therapeutics (COAG) has also consistently gained the trust of the capital market, raising $55 million in Series A in 2021, followed by $135 million in Series B and $157 million in Series C. Wall Street investors believe that these companies, which have raised large amounts of capital, are likely to become targets for major pharmaceutical companies in the future. In particular, with the boom in the obesity treatment market, the neuropsychiatric and rare disease areas are also emerging as key candidates for large M&A, based on their high market expansion potential.

Why It Matters

The market for major depressive disorder (MDD) treatments is projected to reach $7.49 billion by 2030, and Seaport Therapeutics (SPTX) is demonstrating its differentiation from existing treatments such as Sage's Zulresso by validating its oral antidepressant SPT-300 in a Phase 2b trial and reducing hepatotoxicity. In addition, Hemab Therapeutics (COAG) is preparing to initiate a Phase 3 trial of its bispecific antibody sutacimig to target the Glanzmann thrombasthenia (GT) market, which is projected to grow to approximately $450 million by 2033, and aims to change the treatment paradigm centered on Novo Nordisk's NovoSeven. The total of $360 million in funds raised by the two companies in this Nasdaq IPO will serve as a financial buffer to offset R&D costs and defend against clinical risks. This indicates that the capital recovery (exit) and valuation criteria for late-stage platform biotech companies are being normalized. Ultimately, for professionals in the pharmaceutical industry, this will be a milestone demonstrating the potential for commercial success of liver metabolism bypass platforms and bispecific antibodies targeting endogenous coagulation factors.